Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06995781

Evaluation of the Safety and Efficacy of PEGAVISION Silicone Hydrogel Daily Disposable Soft Contact Lenses (G3)

Sponsor: Pegavision Corporation

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if PEGAVISION Silicone Hydrogel Daily Disposable Soft Contact Lenses (G3) are safe and effective for vision correction in adults. It will also assess the comfort and overall experience of wearing these lenses. The main questions it aims to answer are: Do PEGAVISION G3 lenses provide vision correction comparable to CooperVision Clariti 1 day contact lenses? What medical problems or discomfort do participants experience when using PEGAVISION G3 lenses? Researchers will compare PEGAVISION G3 lenses to CooperVision Clariti 1 day contact lenses to determine if they are a safe and effective option for daily vision correction.

Official title: A Multicenter, Randomized, Double-blind, Parallel, Controlled Study Assessing the Safety and Efficacy of PEGAVISION Silicone Hydrogel Daily Disposable Soft Contact Lenses (G3)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

69

Start Date

2025-01-21

Completion Date

2025-08-14

Last Updated

2026-08-20

Healthy Volunteers

No

Interventions

DEVICE

Experimental Intervention

Name: PEGAVISION G3 Silicone Hydrogel Daily Disposable Soft Contact Lenses Type: Medical Device (Investigational) Description: Participants in this arm will wear PEGAVISION G3 daily disposable silicone hydrogel soft contact lenses for three months to evaluate their safety, efficacy, and comfort compared to the control group.

DEVICE

Active Comparator Intervention

Name: CooperVision Clariti 1 day Soft Contact Lenses Type: Medical Device (Approved Comparator) Description: Participants in this arm will wear Clariti 1 day daily disposable soft contact lenses, serving as the control group for comparison with PEGAVISION G3 lenses. Both interventions involve daily wear for at least 8 hours per day, 5 days per week, over a 3-month period, with periodic assessments of visual acuity, safety, and comfort.